NCT05724511 is a Phase 4 clinical trial of MIYAIRI 588 in Depression Mild, sponsored by China Medical University Hospital.

Who is sponsoring NCT05724511?

NCT05724511 is sponsored by China Medical University Hospital.

What drugs are being tested in NCT05724511?

Interventions in NCT05724511: MIYAIRI 588.

What condition does NCT05724511 study?

NCT05724511 studies Depression Mild, Cardiovascular Diseases.

Is NCT05724511 still recruiting?

NCT05724511 is currently completed. Last updated 22 September 2023.

Last reviewed 2023-09-22 · How we verify

NCT05724511

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Probiotics on Depression Syndrome and Risk Factors of Cardiovascular Disease in Hemodialysis Patients

Completed Phase 4 Last updated 22 September 2023

What this trial tests

Phase 4 trial testing MIYAIRI 588 in Depression Mild in 55 participants. Completed in 31 July 2023.

Timeline

27 February 2023

Primary endpoint
30 June 2023

31 July 2023

Quick facts

Lead sponsor	China Medical University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	55
Start date	27 February 2023
Primary completion	30 June 2023
Estimated completion	31 July 2023
Sites	1 location across Taiwan

Drugs / interventions tested

MIYAIRI 588 — full drug profile →

Conditions studied

Depression Mild — all drugs for Depression Mild →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

China Medical University Hospital

Who can join

20 and older, any sex, with Depression Mild or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As the investigators know, only few researches focus on the effect of probiotics on depression in hemodialysis patients. Besides, probiotics also have benefit effect on dyslipidemia and hypertension in general population. Both of them are the risk factors of cardiovascular disease which is the major cause of death in hemodialysis patients. Therefore, this study looks for the effect of probiotics on depression syndrome and risk factors of cardiovascular disease in hemodialysis patients. This is a randomized controlled trial. All patients will be assigned at random to intervention group or control group. This study plans to recruit 70 hemodialysis patients and expects at least 30 patients in each group at the end of study period. The investigators provide probiotics (C. butyricum MIYAIRI 588) to intervention group and provide nothing to the control group. All patients need to maintain the lifestyle during study period. Genomic analysis of gut microbiota on patients' fecal samples will be used to evaluation their compliance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Synbiotics, prebiotics and probiotics for people with chronic kidney disease.
Cooper TE, Khalid R, Chan S, Craig JC, et al · · 2023 · cited 35× · PMID 37870148 · DOI 10.1002/14651858.cd013631.pub2

Verify or expand the search:

Other trials of MIYAIRI 588

Trials testing the same drug.

NCT05759741 — Alterations of Gut Microbiome, Function, and Its Intervention After Defunctioning Ileostomy · EARLY_PHASE1 · unknown

Other recruiting trials for Depression Mild

Currently open trials in the same condition.

NCT06735885 — fMRI Neurofeedback With Matter Neuroscience App · NA · recruiting
NCT06456931 — A Pilot Study Comparing the Efficacy of Traditional Buddhist Mindfulness Training Versus Secular Mindfulness-based Cogni · NA · recruiting
NCT06374056 — Kintsugi Voice Device Pilot Study · active not recruiting
NCT06273995 — Telehealth Behavioral Activation for Teens · NA · recruiting
NCT05788198 — Integrated Depression Care · NA · recruiting

Other China Medical University Hospital trials

Trials by the same sponsor.

NCT07525700 — The Effects of Combining Electronic Picture Books With RPG-Based Gamified Learning on Nursing Students' Motivation and L · NA · not yet recruiting
NCT07463391 — Chinese Classics Recitation Training in Subjective Cognitive Decline · NA · not yet recruiting
NCT07482189 — Effectiveness and Efficiency of an Upper Limb Active-Passive Exoskeleton Robot in Patients With Frozen Shoulder · NA · not yet recruiting
NCT07437144 — Exploring the Effects of Shangshou Daoyin Method on Improving Sleep Quality, Quality of Life, and TCM Constitution in Br · NA · not yet recruiting
NCT07232667 — Digital Technology for Active and Healthy Ageing in Taiwan · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05724511 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Medical University Hospital
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing